Arcus Biosciences Inc - ESG Rating & Company Profile powered by AI
Complete Sustainability analysis of Arcus Biosciences Inc can be reached by signing up for free. If you work at Arcus Biosciences Inc and you would like to licence your ESG rating, please get in touch. Alternative companies in the scoring industry group for Arcus Biosciences Inc are displayed below.
Arcus Biosciences Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 2.7, social score of 4.6 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Atreca Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Arcus Biosciences Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Arcus Biosciences Inc report the average age of the workforce?
Sign up for free to unlockDoes Arcus Biosciences Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Arcus Biosciences Inc offer flexible work?
Sign up for free to unlockDoes Arcus Biosciences Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Arcus Biosciences Inc conduct supply chain audits?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Arcus Biosciences Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose water use targets?
Sign up for free to unlockDoes Arcus Biosciences Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Arcus Biosciences Inc have a product recall in the last two years?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Arcus Biosciences Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Arcus Biosciences Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose parental leave metrics?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Arcus Biosciences Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Arcus Biosciences Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Arcus Biosciences Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose its waste policy?
Sign up for free to unlockDoes Arcus Biosciences Inc report according to TCFD requirements?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose energy use targets?
Sign up for free to unlockDoes Arcus Biosciences Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Arcus Biosciences Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Arcus Biosciences Inc
These potential risks are based on the size, segment and geographies of the company.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.